title: Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy.
abstract: Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema. We report a case of PCV resistant to PDT and ranibizumab, which responded well to intravitreal ziv-aflibercept.
authors.affiliation: Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Chetan
authors.initials: C
authors.lastname: Videkar
authors.affiliation: Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Aditya
authors.initials: A
authors.lastname: Kapoor
authors.affiliation: LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Jay
authors.initials: J
authors.lastname: Chhablani
authors.affiliation: Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Raja
authors.initials: R
authors.lastname: Narayanan
mesh_terms: D000368:Aged; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D058449:Intravitreal Injections; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D000069579:Ranibizumab / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*
chemical_list: D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab